Dr. Martin is the Chairman and CEO of Adjuvance Technologies, a vaccine adjuvant company, with headquarters in Lincoln, NE. He has more than 25 years’ experience developing innovative products in the biotechnology industry. He has led development activities to support more than 100 Investigational New Drug (IND) Applications, and developed four products, 2 vaccines and 2 antibiotics, that eventually received FDA or EMA approval. He has held senior leadership positions in a number of biotech companies including Chiron, Sangamo, and Dynavax.
Dr. Martin received a bachelor’s degree with honors from the University of Nebraska at Kearney, and an MD degree from the University of Nebraska College of Medicine. He was a resident in Pediatrics at the University of Nebraska Medical Center and was a post-doctoral fellow in Molecular Microbiology and Pediatric Infectious Diseases at Washington University in St. Louis.